P.C.M. van de Kerkhof

23.0k total citations · 2 hit papers
498 papers, 15.9k citations indexed

About

P.C.M. van de Kerkhof is a scholar working on Dermatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, P.C.M. van de Kerkhof has authored 498 papers receiving a total of 15.9k indexed citations (citations by other indexed papers that have themselves been cited), including 299 papers in Dermatology, 280 papers in Immunology and 73 papers in Pathology and Forensic Medicine. Recurrent topics in P.C.M. van de Kerkhof's work include Psoriasis: Treatment and Pathogenesis (265 papers), Dermatology and Skin Diseases (214 papers) and Autoimmune Bullous Skin Diseases (61 papers). P.C.M. van de Kerkhof is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (265 papers), Dermatology and Skin Diseases (214 papers) and Autoimmune Bullous Skin Diseases (61 papers). P.C.M. van de Kerkhof collaborates with scholars based in Netherlands, United States and Germany. P.C.M. van de Kerkhof's co-authors include E.M.G.J. de Jong, P.E.J. van Erp, Marieke M.B. Seyger, Andrea W.M. Evers, M. Gerritsen, Joost Schalkwijk, J.B.M. Boezeman, Floris W. Kraaimaat, R.J.B. Driessen and Marcel C. Pasch and has published in prestigious journals such as The Lancet, Nature Genetics and SHILAP Revista de lepidopterología.

In The Last Decade

P.C.M. van de Kerkhof

490 papers receiving 15.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

2005 557 citations C.E.M. Griffiths, P.C.M. van de Kerkhof et al. British Journal of Dermatology profile →
Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

2014 411 citations Mark Lebwohl, Juliet N. Barker et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P.C.M. van de Kerkhof Netherlands	61	8.9k	8.0k	2.1k	2.0k	1.8k	498	15.9k
C. Paul France	68	8.8k 1.0×	8.8k 1.1×	1.9k 0.9×	2.0k 1.0×	3.0k 1.6×	420	16.5k
A.Y. Finlay United Kingdom	70	6.7k 0.8×	15.1k 1.9×	2.3k 1.1×	1.8k 0.9×	2.3k 1.3×	273	22.5k
Ulrich Mrowietz Germany	60	7.5k 0.8×	5.9k 0.7×	1.3k 0.6×	1.5k 0.7×	1.4k 0.7×	331	12.7k
Wolf‐Henning Boehncke Germany	55	8.7k 1.0×	4.4k 0.5×	859 0.4×	1.3k 0.6×	2.7k 1.5×	356	13.2k
Enno Christophers Germany	66	10.1k 1.1×	6.0k 0.7×	1.9k 0.9×	1.4k 0.7×	2.0k 1.1×	362	18.9k
Giampiero Girolomoni Italy	81	12.5k 1.4×	9.9k 1.2×	2.4k 1.1×	2.0k 1.0×	3.7k 2.0×	558	23.7k
L. Puig Spain	57	11.2k 1.3×	7.7k 1.0×	2.5k 1.2×	2.2k 1.1×	3.8k 2.0×	626	18.2k
Charles N. Ellis United States	58	4.4k 0.5×	5.9k 0.7×	971 0.5×	1.5k 0.8×	1.4k 0.8×	235	11.6k
John Koo United States	55	8.0k 0.9×	6.8k 0.9×	835 0.4×	1.4k 0.7×	1.7k 0.9×	339	12.5k
Hidemi Nakagawa Japan	51	5.3k 0.6×	5.2k 0.6×	733 0.3×	1.3k 0.6×	1.6k 0.8×	279	9.5k

Countries citing papers authored by P.C.M. van de Kerkhof

Since Specialization

Citations

This map shows the geographic impact of P.C.M. van de Kerkhof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P.C.M. van de Kerkhof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P.C.M. van de Kerkhof more than expected).

Fields of papers citing papers by P.C.M. van de Kerkhof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P.C.M. van de Kerkhof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P.C.M. van de Kerkhof. The network helps show where P.C.M. van de Kerkhof may publish in the future.

Co-authorship network of co-authors of P.C.M. van de Kerkhof

This figure shows the co-authorship network connecting the top 25 collaborators of P.C.M. van de Kerkhof. A scholar is included among the top collaborators of P.C.M. van de Kerkhof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P.C.M. van de Kerkhof. P.C.M. van de Kerkhof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nakamura, Mio, Andrew Alexis, Ángela Londoño, et al.. (2025). Psoriasis in People With Skin of Color: An Evidence‐Based Update. International Journal of Dermatology. 64(4). 667–677. 2 indexed citations

Kouwenhoven, T., et al.. (2023). Effectiveness of systemic treatments on pruritus associated with atopic dermatitis: A systematic review in pediatric patients. Pediatric Dermatology. 41(1). 34–40. 3 indexed citations

Bronkhorst, Ewald M., G.A.M. Krekels, Simone van der Geer, et al.. (2021). Predictors of surgical treatment burden, outcomes, and overall survival in older adults with basal cell carcinoma: Results from the prospective, multicenter BATOA cohort. Journal of the American Academy of Dermatology. 86(5). 1010–1019. 9 indexed citations

Blauvelt, Andrew, C. Paul, P.C.M. van de Kerkhof, et al.. (2020). Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies. British Journal of Dermatology. 184(4). 640–651. 15 indexed citations

Garcovich, Simone, Ketty Peris, Giuseppe Colloca, et al.. (2020). Frailty screening in dermato‐oncology practice: a modified Delphi study and a systematic review of the literature. Journal of the European Academy of Dermatology and Venereology. 35(1). 95–104. 14 indexed citations

Kerkhof, P.C.M. van de & Frank R. de Gruijl. (2020). Phototherapy in the perspective of the chronicity of psoriasis. Journal of the European Academy of Dermatology and Venereology. 34(5). 926–931. 13 indexed citations

Mertens, Jorre S., Marieke M.B. Seyger, Wietske Kievit, et al.. (2014). Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease. British Journal of Dermatology. 172(3). 722–728. 46 indexed citations

Everdingen, J.J.E. van, et al.. (2014). A national study on adherence to a basal cell carcinoma guideline; development of a tool to assess guideline adherence. British Journal of Dermatology. 172(4). 1008–1013. 6 indexed citations

Lümig, P.P.M. van, S.P. Menting, J. M. P. A. van den Reek, et al.. (2014). An increased risk of non‐melanoma skin cancer during TNF‐inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease‐related factors. Journal of the European Academy of Dermatology and Venereology. 29(4). 752–760. 51 indexed citations

10.

Verhoeven, E.W.M., Floris W. Kraaimaat, Chris van Weel, et al.. (2008). Skin Diseases in Family Medicine: Prevalence and Health Care Use. The Annals of Family Medicine. 6(4). 349–354. 60 indexed citations

11.

Boehncke, Wolf‐Henning, Juliet N. Barker, Sergio Chimenti, et al.. (2006). Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. Journal of the European Academy of Dermatology and Venereology. 20(8). 988–998. 31 indexed citations

12.

Kerkhof, P.C.M. van de. (2005). Handbook of Dermatology drug therapy.. Journal of Dermatological Treatment. 16. 1–1. 10 indexed citations

13.

Krueger, Gerald G., Kenneth B. Gordon, P.C.M. van de Kerkhof, & Wolfram Sterry. (2003). Repeated courses of IM alefacept in psoriasis Rationale and design of an international study that mimics the clinical practice setting. Journal of Investigative Dermatology. 121(1). 339. 7 indexed citations

14.

Tjioe, Milan, T. Smits, Willeke A.M. Blokx, P.C.M. van de Kerkhof, & Marie‐Jeanne P. Gerritsen. (2003). High‐dose long wave visible light induces perinuclear vacuolization in vivo but does not result in early photoageing and apoptosis. Experimental Dermatology. 12(5). 610–614. 3 indexed citations

15.

Kerkhof, P.C.M. van de. (1998). Follicular cysts and hyperkeratoses in early mycosis fungoides. International Journal of Dermatology. 37(9). 696–698. 1 indexed citations

16.

Schalkwijk, Joost, et al.. (1998). A Histological and Immunohistochemical Study on Chronic Irritant Contact Dermatitis. Dermatitis. 9(1). 23–28. 2 indexed citations

17.

Kerkhof, P.C.M. van de, et al.. (1997). Gecombineerde dag-en thuisbehandeling van psoriasis met kort-contact-dithranolapplicaties. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 7. 140–144. 1 indexed citations

18.

Valk, P.G.M. van der, et al.. (1996). Toxic Pustuloderma associated with clemastine therapy. Clinical and Experimental Dermatology. 21(4). 293–295. 6 indexed citations

19.

Alkemade, Hans, et al.. (1994). Demonstration of skin‐derived antileukoproteinase (skalp) and its target enzyme human leukocyte elastase in squamous cell carcinoma. The Journal of Pathology. 174(2). 121–129. 27 indexed citations

20.

Vlijmen‐Willems, Ivonne M.J.J. van, et al.. (1993). Normal human skin demonstrates marked site-variation of tenascin expression, not correlated to epidermal proliferation (Ki-67 binding). Journal of Dermatological Science. 5(1). 54–57. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact